Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Citigroup Upgrades Rigel Pharmaceuticals to Buy

Citigroup Upgrades Rigel Pharmaceuticals to Buy

Citigroup analyst Yigal Nochomovitz upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Neutral to Buy.

byBenzinga Newsdesk

December 2, 2022

1 minute read

Citigroup analyst Yigal Nochomovitz upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Neutral to Buy.

Truist Securities Upgrades MGM Resorts Intl to Buy, Raises Price Target to $50

By Benzinga Newsdesk

December 5, 8:14 AM

Truist Securities analyst Barry Jonas upgrades MGM Resorts Intl (NYSE:MGM) from Hold to Buy and raises the price target from $40 to $50.

MGM

What’s Going On With British Chipmaker Arm Stock Monday?

By Anusuya Lahiri

February 12, 2:22 PM

British chip designer Arm Holdings (NASDAQ: ARM) stock rose 30%, gaining $100B in market cap. Success attributed to Armv9 chips & strong demand.

ARM

Analyst Ratings

Expert Ratings for Editas Medicine

By Benzinga Insights

September 29, 11:00 AM

Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

EDIT

Are Facebook And Instagram Underreporting Harmful Content? Mark Zuckerberg’s Meta Faces More Serious Claims

By Ananya Gairola

November 27, 2:10 AM

The complaint, filed on behalf of 33 states, accuses Meta of publishing quarterly Community Standards Enforcement Reports or CSER that portray low rates of community standards violations.

Citigroup Upgrades Rigel Pharmaceuticals to Buy

Related Posts

Truist Securities Upgrades MGM Resorts Intl to Buy, Raises Price Target to $50

What’s Going On With British Chipmaker Arm Stock Monday?

Expert Ratings for Editas Medicine

Are Facebook And Instagram Underreporting Harmful Content? Mark Zuckerberg’s Meta Faces More Serious Claims